Atopic dermatitis (AD), also known as atopic eczema, is an inflammatory skin disease that is pruritic and recurrent. Since the 2000s, the discovery of a preventive treatment for this severe dermatosis has been a special line of research in the dermatological industry.
In this context, BIOalternatives proposes a range of in vitro tests to select and characterise compounds for the treatment of this pathology.
Epidemiology
AD is the most common dermatosis affecting children: 65% of the patients are less than a year old and 85% are below 5 years.1 The prevalence of this pathology is constantly on the rise and currently affects 10% to 25% of the population.2 This increase is related to the lifestyle in industrialised countries, where 20% of the children suffer from this dermatosis.3
Log in or register FREE to read the rest
This story is Premium Content and is only available to registered users. Please log in at the top of the page to view the full text.
If you don't already have an account, please register with us completely free of charge.
